BTAI CIK: 1720893

BioXcel Therapeutics, Inc.

  • United States
  • Healthcare
  • Drug Manufacturers - Specialty & Generic
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
237
FY22:
203
FY23:
72.1
FY24:
37.4
FY25:
44.7
(positive)
Change from FY21 to FY25
millions USD
FY21:
2.63
FY22:
2.99
FY23:
1.56
FY24:
0.94
FY25:
0.23
Total assets
Change from FY21 to FY25
millions USD
FY21:
239
FY22:
206
FY23:
73.7
FY24:
38.3
FY25:
44.9

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
16.7
FY22:
32.9
FY23:
27.3
FY24:
22.2
FY25:
53.9
(negative)
Change from FY21 to FY25
millions USD
FY21:
1.11
FY22:
96.2
FY23:
103
FY24:
109
FY25:
86.5
(positive)
Change from FY21 to FY25
millions USD
FY21:
222
FY22:
76.8
FY23:
−56.5
FY24:
−93.1
FY25:
−95.5
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
239
FY22:
206
FY23:
73.7
FY24:
38.3
FY25:
44.9

All amounts in millions USD Data sources:SEC EDGARTwelve Data